Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: Results from the ACRIN 6677/RTOG 0625 Central Reader Study

Neuro-Oncology

Volumn 15, Issue 7, 2013, Pages 945-954

  Boxerman, Jerrold L ^a   Zhang, Zheng ^b   Safriel, Yair ^c   Larvie, Mykol ^d   Snyder, Bradley S ^b   Jain, Rajan ^e   Chi, T Linda ^f   Sorensen, A Gregory ^d   Gilbert, Mark R ^f   Barboriak, Daniel P ^g  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e HENRY FORD HOSPITAL   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

bevacizumab and irinotecan; imaging biomarker; overall survival; progression; recurrent glioblastoma

Indexed keywords

BEVACIZUMAB; IRINOTECAN; TEMOZOLOMIDE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; FEMALE; GLIOBLASTOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROIMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL PREDICTION; TUMOR RECURRENCE;

BEVACIZUMAB AND IRINOTECAN; IMAGING BIOMARKER; OVERALL SURVIVAL; PROGRESSION; RECURRENT GLIOBLASTOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CAMPTOTHECIN; CONTRAST MEDIA; DACARBAZINE; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; IMAGING, THREE-DIMENSIONAL; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84879326946     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not049     Document Type: Article

References (51)

1. Norden AD, Drappatz J, Wen PY. Novel anti-angiogenic therapies formalignant gliomas. Lancet neurology. 2008; 7(12): 1152-1160.
2. Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. The Lancet Oncology. 2009; 10(5): 459-466.
3. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine. 2005; 352(10): 987-996. (Pubitemid 40349501)
4. Ballman KV, Buckner JC, Brown PD, et al. The relationship between sixmonth progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro-Oncology. 2007; 9(1): 29-38. (Pubitemid 46543486)
5. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999; 284(5422): 1994-1998. (Pubitemid 29309448)
6. Duda DG, Batchelor TT, Willett CG, Jain RK. VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends in Molecular Medicine. 2007; 13(6): 223-230. (Pubitemid 46836870)
7. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme. The Oncologist. 2009; 14(11): 1131-1138.
8. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28): 4733-4740.
9. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol. 2007; 25(30): 4722-4729. (Pubitemid 350086473)
10. Ali SA, McHayleh WM, Ahmad A, et al. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases. J Neurosurg. 2008; 109(2): 268-272.
11. Vredenburgh JJ, Desjardins A, ReardonDA, Friedman HS. Experience with irinotecan for the treatment of malignant glioma. Neuro-Oncology. 2009; 11(1): 80-91.
12. Jakobsen JN, Hasselbalch B, Stockhausen MT, Lassen U, Poulsen HS. Irinotecan and bevacizumab in recurrent glioblastoma multiforme. Expert Opinion on Pharmacotherapy. 2011; 12(5): 825-833.
13. Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol. 2011; 6: 2.
14. Gil MJ, de Las Penas R, Reynes G, et al. Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO). Anti-Cancer Drugs. 2012; 23(6): 659-665.
15. Moller S, Grunnet K, Hansen S, et al.Aphase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy. Acta Oncol. 2012; 51(6): 797-804.
16. Macdonald DR, Cascino TL, Schold SC, Jr., Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8(7): 1277-1280. (Pubitemid 20195640)
17. Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neurooncology working group. J Clin Oncol. 2010; 28(11): 1963-1972.
18. Vredenburgh JJ, Desjardins A, Herndon JE, 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007; 13(4): 1253-1259. (Pubitemid 46424067)
19. Hygino da Cruz LC, Jr., Rodriguez I, Domingues RC, Gasparetto EL, SorensenAG. Pseudoprogression andpseudoresponse: imagingchallenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol. 2011; 32(11): 1978-1985.
20. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008; 70(10): 779-787.
21. Zuniga RM, Torcuator R, Jain R, et al. Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. Journal of Neuro-Oncology. 2009; 91(3): 329-336.
22. Brandes AA, Tosoni A, Spagnolli F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro-Oncology. 2008; 10(3): 361-367.
23. Prados M, Cloughesy T, Samant M, et al. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 2011; 13(1): 143-151.
24. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro-Oncology. 2011; 13(4): 401-409.
25. Radbruch A, Lutz K, Wiestler B, et al. Relevance of T2 signal changes in the assessment of progression of glioblastoma according to the Response Assessment in Neurooncology criteria. Neuro-Oncology. 2012; 14(2): 222-229.
26. Gallego Perez-Larraya J, Lahutte M, Petrirena G, et al. Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro-Oncology. 2012; 14(5): 667-673.
27. Fink J, Born D, Chamberlain MC. Pseudoprogression: relevance with respect to treatment of high-grade gliomas. Current Treatment Options in Oncology. 2011; 12(3): 240-252.
28. Brandsma D, Stalpers L, TaalW, Sminia P, van den Bent MJ. Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. The Lancet Oncology. 2008; 9(5): 453-461. (Pubitemid 351597795)
29. Chamberlain MC, Glantz MJ, Chalmers L, Van Horn A, Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. Journal of Neuro-Oncology. 2007; 82(1): 81-83.
30. Taal W, Brandsma D, de Bruin HG, et al. Incidence of early pseudoprogression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer. 2008; 113(2): 405-410.
31. Gerstner ER, McNamara MB, Norden AD, Lafrankie D, Wen PY. Effect of adding temozolomide to radiation therapy on the incidence of pseudo-progression. Journal of Neuro-Oncology. 2009; 94(1): 97-101.
32. Chaskis C, Neyns B, Michotte A, De Ridder M, Everaert H. Pseudoprogression after radiotherapy with concurrent temozolomide for high-grade glioma: clinical observations and working recommendations. Surgical Neurology. 2009; 72(4): 423-428.
33. Sanghera P, Perry J, Sahgal A, et al. Pseudoprogression following chemoradiotherapy for glioblastoma multiforme. The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 2010; 37(1): 36-42.
34. Brandes AA, Franceschi E, Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26(13): 2192-2197.
35. Roldan GB, Scott JN, McIntyre JB, et al. Population-based study of pseudoprogression after chemoradiotherapy inGBM. TheCanadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques. 2009; 36(5): 617-622.
36. Clarke JL, Chang S. Pseudoprogression andpseudoresponse: challenges in brain tumor imaging. Current Neurology and Neuroscience Reports. 2009; 9(3): 241-246.
37. Brandsma D, van den Bent MJ. Pseudoprogression and pseudoresponse in the treatment of gliomas. Current Opinion in Neurology. 2009; 22(6): 633-638.
38. van den Bent MJ, Vogelbaum MA, Wen PY, Macdonald DR, Chang SM. End point assessment in gliomas: novel treatments limit usefulness of classical Macdonald's Criteria. J Clin Oncol. 2009; 27(18): 2905-2908.
39. Paldino MJ, Desjardins A, Friedman HS, Vredenburgh JJ, Barboriak DP. A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiforme. The British Journal of Radiology. 2012; 85(1012): 382-389.
40. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. Journal of Neuro-Oncology. 2011; 105(1): 91-101.
41. Mangla R, Singh G, Ziegelitz D, et al. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma. Radiology. 2010; 256(2): 575-584.
42. Essock-Burns E, Lupo JM, Cha S, et al. Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma. Neuro-oncology. 2011; 13(1): 119-131.
43. Kim H, Catana C, Ratai EM, et al. Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. Cancer Res. 2011; 71(11): 3745-3752.
44. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009; 69(13): 5296-5300.
45. Jain R, Scarpace LM, Ellika S, et al. Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. Journal of Neuro-Oncology. 2010; 96(3): 423-431.
46. Pope WB, Young JR, Ellingson BM. Advances in MRI assessment of gliomas and response to anti-VEGF therapy. Current Neurology and Neuroscience Reports. 2011; 11(3): 336-344.
47. Quant EC, Wen PY. Response assessment in neuro-oncology. Current Oncology Reports. 2011; 13(1): 50-56.
48. Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK. Response criteria for glioma. Nature Clinical Practice. Oncology. 2008; 5(11): 634-644.
49. Pope WB, Hessel C. Response assessment in neuro-oncology criteria: implementation challenges in multicenter neuro-oncology trials. AJNRAmJ Neuroradiol. 2011; 32(5): 794-797.
50. Galanis E, Buckner JC, Maurer MJ, et al. Validation of neuroradiologic response assessment in gliomas: measurement by RECIST, twodimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro-Oncology. 2006; 8(2): 156-165. (Pubitemid 46542660)
51. Shah GD, Kesari S, Xu R, et al. Comparison of linear and volumetric criteria in assessing tumor response in adult high-grade gliomas. Neuro-Oncology. 2006; 8(1): 38-46. (Pubitemid 43154449)